All In Biotech

Drug Trial Radar · NCT04636983

Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 in Male Subjects

A Phase I, Single-centre, Double-blind, Randomised, Placebo-controlled Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 Administered as Single Intravenous Doses to Healthy Male Subjects

Last checked: Nov 19, 2026Latest source record: Feb 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

54

Actual

Start

Nov 9, 2020

Primary completion

Dec 12, 2021

Study completion Jan 20, 2022

Sponsor

Lead sponsor
BioVersys SASIndustry
Sponsor type
Industry
First posted
Nov 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, single-centre, double-blind, randomised, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single intravenous ascending doses of BV100 to healthy male subjects.

Conditions

  • Healthy Subjects

Interventions

  • BV100Drug

    Rifabutin IV

  • PlaceboDrug

    Saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To investigate the safety and tolerability of single intravenous ascending doses of BV100 assessed by the nature, occurrence, and severity of treatment-emergent adverse eventsTime frame: 10 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nuvisan GmbH

    Neu-Ulm, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.